CN118354770A - 具有gabaa受体活性的类黄酮衍生物及使用方法 - Google Patents

具有gabaa受体活性的类黄酮衍生物及使用方法 Download PDF

Info

Publication number
CN118354770A
CN118354770A CN202280080629.4A CN202280080629A CN118354770A CN 118354770 A CN118354770 A CN 118354770A CN 202280080629 A CN202280080629 A CN 202280080629A CN 118354770 A CN118354770 A CN 118354770A
Authority
CN
China
Prior art keywords
compound
bond
independently
group
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280080629.4A
Other languages
English (en)
Chinese (zh)
Inventor
E·凯瑞
J·E·西蒙
J·罗贝热
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Medicine And Dentistry New Jersey Medical School
Original Assignee
University Medicine And Dentistry New Jersey Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Medicine And Dentistry New Jersey Medical School filed Critical University Medicine And Dentistry New Jersey Medical School
Publication of CN118354770A publication Critical patent/CN118354770A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280080629.4A 2021-10-07 2022-10-06 具有gabaa受体活性的类黄酮衍生物及使用方法 Pending CN118354770A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163253341P 2021-10-07 2021-10-07
US63/253,341 2021-10-07
PCT/US2022/045904 WO2023059802A1 (en) 2021-10-07 2022-10-06 Flavonoid derivatives with gabaa receptor activity and methods of use

Publications (1)

Publication Number Publication Date
CN118354770A true CN118354770A (zh) 2024-07-16

Family

ID=85803715

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280080629.4A Pending CN118354770A (zh) 2021-10-07 2022-10-06 具有gabaa受体活性的类黄酮衍生物及使用方法

Country Status (7)

Country Link
US (1) US20240398821A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412605A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024538721A (cg-RX-API-DMAC7.html)
CN (1) CN118354770A (cg-RX-API-DMAC7.html)
AU (1) AU2022361421A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233822A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023059802A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS604831B2 (ja) * 1975-10-20 1985-02-06 中外製薬株式会社 4(3h)−キナゾリノン誘導体の製法
US5258478A (en) * 1992-04-27 1993-11-02 Florida State University Low self-absorbing, intrinsically scintillating polymers
GB9521184D0 (en) * 1995-10-17 1995-12-20 Univ Strathclyde Flavonoids
RU2214405C2 (ru) * 1998-02-18 2003-10-20 НьюроСёрч А/С Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US7846915B2 (en) * 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
CA2808680A1 (en) * 2010-08-24 2012-03-01 The Regents Of The University Of California Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
CN106478525A (zh) * 2015-08-28 2017-03-08 南京理工大学 一种合成喹唑酮的方法
CN109879820B (zh) * 2019-02-26 2022-07-19 扬州大学 一种喹唑啉酮杂环化合物的合成方法

Also Published As

Publication number Publication date
JP2024538721A (ja) 2024-10-23
EP4412605A4 (en) 2025-07-30
CA3233822A1 (en) 2023-04-13
US20240398821A1 (en) 2024-12-05
EP4412605A1 (en) 2024-08-14
AU2022361421A1 (en) 2024-05-09
WO2023059802A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
RU2339624C2 (ru) Производные аминоиндазолов и их применение в качестве ингибиторов киназ
CN102958937B (zh) 作为磷酸二酯酶抑制剂的苯并二氧杂环戊烯或苯并二氧杂环庚烯杂环化合物
EP2547676B1 (en) Modulators of hec1 activity and methods therefor
EP1537087A1 (fr) Derives de 3-aminoindazole comme inhibiteurs de kinase et compositions pharmaceutiques les renfermant
FR2613934A1 (fr) Composition pharmaceutique a base de 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl) methyl)-4h-carbazol-4-one et de la ranitidine, son procede de fabrication, l'utilisation de ses deux principes actifs pour la fabrication d'un medicament
EA004539B1 (ru) Комбинационная терапия для лечения резистентной депрессии
WO1993000094A2 (en) Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
EP2294068B1 (fr) DERIVES DE 1,3-DIHYDRO-2H-PYRROLO(3,2-b) PYRIDIN-2-ONE, LEUR PREPARATION ET LEURS APPLICATIONS EN THERAPEUTIQUE
JPH11508920A (ja) 2,7―置換オクタヒドロ―ピロロ[1,2―a]ピラジン誘導体
CN102869665B (zh) 苯并氮杂环庚三烯化合物
EP2735567A1 (en) Heterocyclic substituted pyrimidine compound
CN112204025B (zh) 用于治疗疼痛的化合物,包含其的组合物以及使用其的方法
JP4236407B2 (ja) 生理活性なゲピロン代謝産物を使用することによって心理的疾患を治療する方法
US20240398821A1 (en) Flavonoid derivatives with gabaa receptor activity and methods of use
WO2020123847A1 (en) Organic compounds
JP3332929B2 (ja) ある種の架橋4−フェニル−2−アミノメチルイミダゾール:新しいドパミン受容体サブタイプ特異的リガンド
HK40115276A (en) Flavonoid derivatives with gabaa receptor activity and methods of use
EP1687314B1 (en) PREPARATION OF 1-AZA-2-OXA-DIBENZO [e,h] AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
CA2544297A1 (en) Use of 2-thia-dibenzo[e, h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
NO313286B1 (no) Guanidinylamino heterocykelforbindelser nyttige som alfa-2 adrenerge reseptoragonister
NO970183L (no) (1H-Indol-4-yl)-piperidin- eller tetrahydropyridin-etylaminer og -etylkarboksamider
WO2025217596A1 (en) Substituted 2,3-dihydro-4h-benzo[e][ 1,3] oxazin-4-one compounds and methods of use thereof
AU2006291059A1 (en) Salicylate and gentisate salts of a piperazine compound
JPH07503240A (ja) 3‐アリールインドールおよび1‐アリールインダゾール誘導体の精神病の治療のための使用
WO2021046789A1 (zh) 吲唑-甲酰胺衍生物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40115276

Country of ref document: HK